Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Sobi and Novimmune selected as Honourees for 2019 National Organization for Rare Disorders (NORD) Rare Impact Award in Industry Innovation for Gamifant® (emapalumab)

Sobi™ and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders (NORD) for the 2019 Rare Impact Awards. The companies were nominated in the category of Industry Innovation in recognition of the US Food and Drug Administration (FDA) approval in November 2018 of Gamifant® (emapalumab-lzsg) for the treatment of paediatric (newborn and older) and adult patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. The Rare Impact Awards recognise

The Nomination Committee of Handicare Group has decided to propose a new member of the Board

Ahead of the Annual General Meeting held on May 8th, 2019 the Nomination Committee of Handicare Group has decided to propose Christina Lindstedt as new director of the Board in Handicare Group.The Nomination Committee proposes that the Board shall be composed of seven directors (unchanged from the current year) elected at the Annual General Meeting, with no deputy members, for the period until the next Annual General Meeting. The Nomination Committee proposes re-election of Lars Marcher, Joakim Andreasson, Jonas Arlebäck, Maria Carell, Johan Ek, Claes Magnus Åkesson and Christina

Finns choose a domestic nicotine-free product as their preferred smoking intervention method

Biohit Oyj and Sanoma Media invited 40 volunteers  to try and quit smoking by using Acetium® lozenge and asked for feedback on their experience of using this alternative method. They received encouraging and positive comments from the users and with the help of Acetium, 93% of the test group reduced smoking significantly or quit smoking completely during the two months of testing. Based on the test group, most people trying to quit smoking are concerned about their health and want to put an end to unnecessary spending. 89% of the test group felt that Acetium® lozenge being nicotine-free

Inhalation Sciences' PreciseInhale center stage at packed Fraunhofer ITEM seminar, SOT 2019

Fraunhofer ITEM (Institute for Toxicology and Experimental Medicine) is one of the world’s leading toxicology research organizations. At the SOT (Society of Toxicology) 2019 Conference in Baltimore it presented innovative research carried out using Inhalation Sciences’ PreciseInhale, to over 100 scientists at a packed exhibitor-hosted seminar.“It was an early seminar right at the beginning of the day—but it was packed” says ISAB CEO Lena Heffler. “The seminar presented PreciseInhale and highly innovative research into animal-free testing carried out using it. The general response was that

Wallenstam selected to participate in the development of Landvetter Södra

Wallenstam will be one of the six construction and property companies that will develop Landvetter Södra together with Landvetter Södra Utveckling AB and Härryda Municipality. Landvetter Södra will be built in a strategic location between Gothenburg and Borås, close to Gothenburg Landvetter Airport. It will be a modern, international, innovative and humane town for at least 25,000 inhabitants.“It feels really great for us to be involved from the start and participate in the development of Landvetter Södra. The plan for Landvetter Södra is to build innovatively and sustainably in line with

Insplorion won the ABB SynerLeap Springboard and expanded its collaboration

Insplorion won, together with Omnio, ABB SynerLeap Springboard in 2019. Now we are developing the cooperation with ABB through a joint project paid by ABB with USD 30,000. The project will investigate process monitoring primarily for water purification. We also win offices at Synerleap, central in Västerås, with direct access to ABB's organization. In our cooperation other areas of interest, in addition to previous battery sensors, are also various types of gas measurements, for example hydrogen gas.SynerLeap is ABB's innovation development hub for startups with its head office located in

Fortum solves major EV sustainability issue - innovation boosts battery recycling rate to over 80%

FORTUM CORPORATION PRESS RELEASE 25 March 2019 Electrification will rapidly increase the need for batteries. A new solution by Nordic clean energy company Fortum makes over 80% of the electric vehicle (EV) battery recyclable, returns the scarce metals back into circulation and resolves the sustainability gap by reducing the need to mine cobalt, nickel, and other scarce metals. "There are very few working, economically viable technologies for recycling the majority of materials in lithium-ion batteries. We saw a challenge that was not yet solved and developed a scalable recycling

HIDDN: Enters into a LOI for a potential business combination with Energos Group, to diversify business to include renewable energy technology.

(Oslo, 25 March 2019) Hiddn Solutions ASA (Hiddn, OSE: HIDDN) has entered into a Letter of Intent (LOI) for a potential business combination with Energos Group AS (Energos) to add new business lines providing technology and solutions to the global renewable energy production industry. “We are pleased to announce the ambition to join forces with Energos to further develop and fuel the growth of an already strong and profitable business line within supplying technology and solutions for renewable energy production. Energos has a solid platform in this global industry and we look forward to

BioArctic’s partner Eisai to give poster presentations on BAN2401 in early Alzheimer’s disease at the AD/PD conference in Lisbon

Stockholm, Sweden, March 25, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that its partner Eisai will give poster presentations related to BAN2401 in early Alzheimer’s disease at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD) on March 27 in Lisbon, Portugal. One poster presentation will highlight the study design for the Open Label Extension portion of the BAN2401 Phase 2b study in patients with early Alzheimer’s disease. Another poster presentation will cover pharmacokinetic and exposure-response analyses for efficacy and safety of

AlzeCure to present at International scientific conference

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that it will have two presentations at AD/PD 2019, the 14th International Conference on Alzheimer’s & Parkinson’s Diseases, March 26-31, in Lisbon, Portugal.Märta Dahlström, who is the lead author of the study, will give her oral presentation on March 27, at 2pm WET (3pm CET).The title of it is: AC-25793, A Positive Modulator of Neurotrophin Signaling, Attenuates Scopolamine-Induced Memory Impairment and Reduces Depression-Like Symptoms in Mice. "In this study, we have within our NeuroRestore platform developed new small

CLS Presents MRI-Guided, Laser Ablation Solutions for Prostate Cancer at CME-Accredited Conferences in London, Paris & Amsterdam

Lund, Sweden – March 25, 2019 - Clinical Laserthermia Systems AB  (publ) (CLS) today announced it will be exhibiting and presenting its High Precision, Image-Guided Laser Ablation Solutions at three CME-Accredited Medical Conferences & Workshops in the UK, France, and Netherlands this April 2019. CLS Thermal Therapy products are currently in use at hospitals and clinics in the U.S. and EU for patient treatments and also undergoing several clinical trials.   “CLS is excited to be participating in these three medical education

CLS Presents Studies for Image-Guided Laser, Heat-Induced Cancer Immunotherapy for Tumors at ECIO 2019

Lund, Sweden – March 25, 2019 - Clinical Laserthermia Systems AB  (publ) (CLS)today announced that clinical studies and results for its imILT®heat-induced cancer immunotherapy for tumors will be presented during a one hour symposium at the European Conference on Interventional Oncology  (ECIO) in Amsterdam, the Netherlands this April 8-11, 2019. The company also will participate in an educational, hands-on workshop for “Tumor ablation” featuring its TRANBERG®|Thermal Therapy System 

Electrolux issues SEK 1 billion Green Bond

Electrolux is issuing the first bond loan within its green bond framework, raising SEK 1 billion to fund investments and other projects with environmental benefits.The bond is being issued under Electrolux existing EMTN (Euro Medium Term Note) program and the recently launched Electrolux Green Bond Framework. The funds raised will be used for financing or refinancing of eligible “green assets” as defined in the framework. The total principal amount of the bond is SEK 1 billion and the issue date for the bond loan will be March 27, 2019, with a maturity on March 27, 2024. The loan has a

Voucher increases for Academedia amount to 2.5% in Sweden

Voucher notifications have been recieved for almost 80 percent of the student base which gives a stable average for the Swedish operations. Average voucher increases for 2019 are for AcadeMedia’s Swedish operations estimated to 2.5 (2.5) percent and 3.4 (2.2) percent for the Norwegian preschools. The increases are in line with the figures provided in AcadeMedia's latest quarterly report. Voucher increases have been calculated based on voucher notifications received and have been weighted with AcadeMedia’s student mix in each segment. As communicated in the most recent interim report

Electrolux highlights lower emissions and investments for improved climate impact in 2018 Sustainability Report

Electrolux, the appliance industry sustainability leader, today reported a 66% reduction in CO2 emissions from its operations since 2005, and highlighted how significant investments at manufacturing sites and in new product platforms will make a major contribution to the company achieving its climate targets.In the 2018 Sustainability Report, released today, Electrolux presents facts and figures showing the company’s progress towards its targets in the nine key areas outlined in its sustainability framework, For the Better. Read the full report here: www.electroluxgroup.com/

Implementation of IFRS 16 Leases, Kesko Group’s restated comparison figures for January-December 2018

IFRS 16 Leases, which took effect on 1 January 2019, addresses the definition, recognition and measurement of lease agreements and other information given in relation to lease agreements in financial statements. According to the standard, the lessee recognises in its balance sheet right-of-use assets and financial liabilities. This release presents Kesko Group’s restated comparison figures for January-December 2018, calculated in accordance with the standard that took effect on 1 January 2019. Kesko Corporation has provided information on the implementation of IFRS 16 Leases in a 19

Share buy-backs in Nordic Waterproofing (to secure the Company’s incentive programs) during week 12, 2019

During the period March 18, 2019, until and including March 22, 2019, Nordic Waterproofing Holding A/S has repurchased in total 11,665 own shares (ISIN: DK0060738409). The share buy-backs form part of the SEK 18 million share buy-back program that Nordic Waterproofing announced on December 20, 2018, in order to secure the Company’s incentive programs. The share buy-back program, which runs between December 20, 2018, and March 29, 2019, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and the Commission Delegated Regulation (EU) No 2016/1052 (the “

Forxiga approved in Europe for type-1 diabetes

25 March 2019 07:00 GMT Forxiga approved in Europe for type-1 diabetes Forxiga is the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes and the first AstraZeneca medicine ever approved for type-1 diabetes The European Commission (EC) has approved Forxiga (dapagliflozin) for use in type-1 diabetes (T1D) as an adjunct to insulin in patients with a BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. This is the first approval of Forxiga for the treatment of patients with T1D.

FOUNDER OF ENCARE AWARDED THE “DISTINGUISHED NUTRITION SUPPORT INTERNATIONAL SERVICE AWARD”

Professor Olle Ljungqvist, the founder of Encare, has been awarded the 2019 Distinguished Nutrition Support International Award in connection with the recently held American Society for Parenteral and Enteral Nutrition (ASPEN) Congress in Phoenix, Arizona. He was awarded “for his exceptional leadership and clinical practice contributions”. Professor Ljungqvist is also one of the founders of ERAS[®] Society (Enhanced Recovery After Surgery), www.erassociety.org, which mission is to develop perioperative care and to improve recovery through research, education, audit and implementation of

Redeye initiates coverage of Beijer Electronics Group

Redeye initiates coverage of Beijer Electronics Group, which offers a play on industrial digitalization, and has emerged from a long turnaround and is now better positioned than ever. While current valuation is fair, BELE should be attractive to long-term investors seeking industrial IoT exposure. We argue that increased profitability and an improved digitalisation positioning should justify an increased valuation over time.  Read more and download the initial research report: http://bit.ly/2WnhXtM

Elekta Unity MR-linac receives Medical Device License from Health Canada

New system for the delivery of radiotherapy using magnetic resonance imaging to enhance personalized cancer treatment in CanadaTORONTO, March 25, 2019 – Elekta (EKTA-B.ST) today announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received a Medical Device License from Health Canada, clearing the technology for commercial sales in Canada. “We are pleased to have achieved this important milestone toward making Elekta Unity available in Canada and expect that this important new treatment option will become available to patients later this year, subsequent

Targovax to hold a webcast with Q&A session

Oslo, Norway, 25 March 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that the Company on Thursday 28 March 2019 13:00 (CET) will hold a live Q&A session with Targovax's senior management. The Q&A session will streamed at Aksjeforum. Please follow this link: http://bit.ly/2HPDTd5 We welcome questions before and during the session. Please send questions in advance to contact@targovax.com (mail%20to:%20contact@targovax.com) or post them in the commentary field below the stream during

There are no items matching the current filter
There are no more items matching the current filter
Back to top